We are live on ! Find out more
AST.WS

Asterias Biotherapeutics Warrants

Delisted

AST.WS was delisted on the 26th of September, 2017.

36 hedge funds and large institutions have $406K invested in Asterias Biotherapeutics Warrants in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less funds holding

Funds holding: 37 → 36 (-1)

96% less capital inflows, than outflows

Capital inflows: $392 | Capital outflows: $10.3K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
36
Holders Change
-1
Holders Change %
-2.7%
% of All Funds
0.9%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
–
Increased
6
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AST.WS Hedge Fund Activity: Q4 2016 in Review

36 of the 4,009 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Warrants (AST.WS) for Q4 2016, worth a combined $406K — up 3.1% from $394K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of AST.WS and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.

The largest buyer was UBS Group, adding an estimated $369. The largest seller was Fidelity Investments, cutting an estimated $7.64K.

  • 36 institutional investors held Asterias Biotherapeutics Warrants (AST.WS) as of Q4 2016, down from 37 in Q3 2016.
  • Funds reported $406K of Asterias Biotherapeutics Warrants stock for Q4 2016, up 3.1% quarter-over-quarter.
  • 0 funds opened new Asterias Biotherapeutics Warrants positions in Q4 2016 and 1 closed out, a net change of -1 holder.
  • The largest Asterias Biotherapeutics Warrants buyer in Q4 2016 was UBS Group, an estimated $369 added.
  • The largest Asterias Biotherapeutics Warrants seller in Q4 2016 was Fidelity Investments, an estimated $7.64K sold.

Based on aggregated 13F filings for Q4 2016.